Pliant Therapeutics
PLRX
88 hedge funds and large institutions have $241M invested in Pliant Therapeutics in 2022 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 27 increasing their positions, 25 reducing their positions, and 23 closing their positions.
102% more call options, than puts
Call options by funds: $2.93M | Put options by funds: $1.45M
9% more capital invested
Capital invested by funds: $222M → $241M (+$19.4M)
8% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 25
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
9% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 23
4.23% less ownership
Funds ownership: 87.55% → 83.32% (-4.2%)
4% less funds holding
Funds holding: 92 → 88 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
+$3.01M |
| 2 |
CA
CHI Advisors
New York
|
+$2.88M |
| 3 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$2.29M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$2.29M |
| 5 |
Goldman Sachs
New York
|
+$1.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$11.1M |
| 2 |
BlackRock
New York
|
-$5.2M |
| 3 |
State Street
Boston,
Massachusetts
|
-$2.31M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.83M |
| 5 |
Walleye Capital
New York
|
-$1.67M |
PLRX Hedge Fund Activity: Q2 2022 in Review
88 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q2 2022, worth a combined $241M — up 8.7% from $222M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of PLRX and 21 opened new positions — a net loss of 2 holders — while 25 trimmed existing stakes and 27 added.
The largest buyer was Laurion Capital Management, opening a new position worth an estimated $3.01M. The largest seller was Fidelity Investments, cutting an estimated $11.1M.
- 88 institutional investors held Pliant Therapeutics (PLRX) as of Q2 2022, down from 92 in Q1 2022.
- Funds reported $241M of Pliant Therapeutics stock for Q2 2022, up 8.7% quarter-over-quarter.
- 21 funds opened new Pliant Therapeutics positions in Q2 2022 and 23 closed out, a net change of -2 holders.
- The largest Pliant Therapeutics buyer in Q2 2022 was Laurion Capital Management, an estimated $3.01M added.
- The largest Pliant Therapeutics seller in Q2 2022 was Fidelity Investments, an estimated $11.1M sold.
Based on aggregated 13F filings for Q2 2022.